secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0000950170-23-017194
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q1 net loss $57.7M; clonoSEQ volume up 57% YoY
-----------------------------------------------------------------------

- Revenue $37.6M (-3% YoY); MRD $21.4M (+20%); Immune Medicine $16.2M (-22% due to Genentech amortization decline).
- clonoSEQ test volume 12,079 (+57% YoY); new Takeda pan-portfolio collaboration for MRD endpoint.
- Net loss $57.7M (vs $62.8M prior); Adjusted EBITDA loss $37.1M (vs $43.1M prior).
- FY2023 revenue guidance reaffirmed $205M-$215M; expects OpEx below FY2022 level of $385.5M.
- Consolidation of President and COO roles under Julie Rubinstein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/0000950170-23-017194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/adpt-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer